Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;64(4):44.
doi: 10.3892/ijo.2024.5632. Epub 2024 Mar 1.

Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)

Jinzhe Sun #  1 , Shiqian Chen #  1 , Dan Zang #  1 , Hetian Sun  2 , Yan Sun  1 , Jun Chen  1
Affiliations
Review

Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)

Jinzhe Sun et al. Int J Oncol. 2024 Apr.

Abstract

Cancer is one of the leading causes of mortality worldwide. The etiology of cancer has not been fully elucidated yet, and further enhancements are necessary to optimize therapeutic efficacy. Butyrate, a short‑chain fatty acid, is generated through gut microbial fermentation of dietary fiber. Studies have unveiled the relevance of butyrate in malignant neoplasms, and a comprehensive understanding of its role in cancer is imperative for realizing its full potential in oncological treatment. Its full antineoplastic effects via the activation of G protein‑coupled receptors and the inhibition of histone deacetylases have been also confirmed. However, the underlying mechanistic details remain unclear. The present study aimed to review the involvement of butyrate in carcinogenesis and its molecular mechanisms, with a particular emphasis on its association with the efficacy of tumor immunotherapy, as well as discussing relevant clinical studies on butyrate as a therapeutic target for neoplastic diseases to provide new insights into cancer treatment.

Keywords: GPCR; HDACI; butyrate; cancer; treatment; tumor immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Illustration of the pathways involved in the synthesis, absorption, and metabolism of butyrate. Glutarate, L-lysate, succinate and non-digestible carbohydrates are the four sources of butyrate that the gut bacteria use. It is absorbed and digested by the intestinal epithelial cells. Little amounts of butyrate enter the liver, where it regulates the metabolism of fatty acids.
Figure 2
Figure 2
The role of butyrate in tumorigenesis. SCFAs are produced by the intestinal microbiome in the fermentation of undigested food fiber, non-digestible carbohydrates, or resistant starch. Butyrate is one of the major SCFAs. The antitumor effect of butyrate is mainly reflected in four aspects: (A) Modulation of immune response; (B) Influences on the tumor inflammatory microenvironment; (C) Induction tumor cell apoptosis; (D) Enhancement of the immunotherapeutic effect and (E) Protection of the intestinal epithelial barrier function. SFCAs, short-chain fatty acids.
Figure 3
Figure 3
Butyrate plays an anticancer role within the human body through the activation of GPCRs. Its primary mode of action involves the regulation of cytokine production and immune cell functionality, achieved primarily by the activation of GPCRs. This activation serves to bolster intestinal barrier function, strengthen the immune system, mitigate inflammation, govern energy metabolism, and impede the progression of tumors. GPCR, G protein-coupled receptor.
Figure 4
Figure 4
Butyrate exerts anticarcinogenic effects through effecting acetylation. The main types of genes affected by butyrate include: (A) tumor immunity-related genes; (B) tumor apoptosis-related genes; (C) cell cycle control-related genes; (D) tumor-related miRNA; (E) tumor cell metabolism-related genes. miRNA or miR, microRNA; HK, hexokinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Danneskiold-Samsøe NB, Dias de Freitas Queiroz Barros H, Santos R, Bicas JL, Cazarin CBB, Madsen L, Kristiansen K, Pastore GM, Brix S, Maróstica Júnior MR. Interplay between food and gut microbiota in health and disease. Food Res Int. 2019;115:23–31. doi: 10.1016/j.foodres.2018.07.043. - DOI - PubMed
    1. Kayama H, Takeda K. Functions of innate immune cells and commensal bacteria in gut homeostasis. J Biochem. 2016;159:141–149. doi: 10.1093/jb/mvv119. - DOI - PMC - PubMed
    1. Kim KN, Yao Y, Ju SY. Short chain fatty acids and fecal microbiota abundance in humans with obesity: A systematic review and meta-analysis. Nutrients. 2019;11:2512. doi: 10.3390/nu11102512. - DOI - PMC - PubMed
    1. Miyamoto J, Kasubuchi M, Nakajima A, Irie J, Itoh H, Kimura I. The role of short-chain fatty acid on blood pressure regulation. Curr Opin Nephrol Hypertens. 2016;25:379–383. doi: 10.1097/MNH.0000000000000246. - DOI - PubMed
    1. Gonçalves P, Araújo JR, Di Santo JP. A Cross-Talk between microbiota-derived short-chain fatty acids and the host mucosal immune system regulates intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:558–572. doi: 10.1093/ibd/izx029. - DOI - PubMed

MeSH terms

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant no. 82203056), the Natural Science Foundation of Liaoning (grant no. 2023-BS-167), the Science and Technology Talent Innovation Support Plan of Dalian (grant no. 2022RQ091) and the '1+X' program for Clinical Competency Enhancement-Clinical Research Incubation Project of the Second Hospital of Dalian Medical University (grant no. 2022LCYJYB01).